2022Interim Report中期報告 CHARACTERISTICS OF GEM OF THE STOCK EXCHANGE OF HONG KONG LIMITED (THE “STOCK EXCHANGE”)GEM has been positioned as a market designed to accommodate small and mid-sized companies to which a higher investment risk may be attached than other companies listed on the Stock Exchange. Prospective investors should be aware of the potential risks of investing in such companies and should make the decision to invest only after due and careful consideration.Given that the companies listed on GEM are generally small and midsized companies, there is a risk that securities traded on GEM may be more susceptible to high market volatility than securities traded on the Main Board of the Stock Exchange and no assurance is given that there will be a liquid market in the securities traded on GEM.Hong Kong Exchanges and Clearing Limited and the Stock Exchange take no responsibility for the contents of this report, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from, or in reliance upon the whole or any part of the contents of this report.This report, for which the directors (the “Directors”) of Shenzhen Neptunus Interlong Bio-technique Company Limited (the “Company”) collectively and individually accept full responsibility, includes particulars given in compliance with the Rules Governing the Listing of Securities on GEM of the Stock Exchange (the “GEM Listing Rules”) for the purpose of giving information with regard to the Company. The Directors of the Company, having made all reasonable enquiries, confirm that to the best of their knowledge and belief the information contained in this report is accurate and complete in all material respects and not misleading or deceptive, and there are no other matters the omission of which would make any statement herein or this report misleading.香港聯合交易所有限公司（「聯交所 」）GEM的特色GEM的定位，乃為中小型公司提供一個上市的市場，此等公司相比起其他在聯交所上市的公司帶有較高投資風險。有意投資的人士應了解投資於該等公司的潛在風險，並應經過審慎周詳的考慮後方可作出投資決定。由於GEM上市公司普遍為中小型公司，在GEM買賣的證券可能會較於聯交所主板買賣之證券承受較大的市場波動風險，同時無法保證在GEM買賣的證券會有高流通量的市場。香港交易及結算所有限公司及聯交所對本報告的內容概不負責，對其準確性或完整性亦不發表任何聲明，並明確表示概不就因本報告全部或任何部分內容而產生或因倚賴該等內容而引致的任何損失承擔任何責任。本報告的資料乃遵照聯交所的《GEM證券上市規則 》（「GEM上市規則」）而刊載，旨在提供有關深圳市海王英特龍生物技術股份有限公司（「本公司」）的資料。本公司的董事（「董事」）願就本報告的資料共同及個別地承擔全部責任。各董事在作出一切合理查詢後，確認就其所知及所信，本報告所載資料在各重要方面均屬準確完備，沒有誤導或欺詐成份，且並無遺漏其他事項，足以令致本報告或其所載任何陳述產生誤導。 1深圳市海王英特龍生物技術股份有限公司 2022年中期報告INTERIM RESULTS (UNAUDITED)The board of directors (the “Board”) of the Company is pleased to present the unaudited condensed consolidated interim financial statements of the Company and its subsidiaries (collectively the “Group”) for the six months ended 30 June 2022 (the “Reporting Period”), together with the unaudited comparative figures for the corresponding period of 2021.CONDENSED CONSOLIDATED STATEMENT OF PROFIT OR LOSS AND OTHER COMPREHENSIVE INCOME (UNAUDITED)簡明綜合損益及其他全面收益表（未經審核）for the three months and six months ended 30 June 2022截至二零二二年六月三十日止三個月及六個月For the three monthsended 30 JuneFor the six monthsended 30 June截至六月三十日止三個月截至六月三十日止六個月2022202120222021二零二二年二零二一年二零二二年二零二一年RMB’000RMB’000RMB’000RMB’000人民幣千元人民幣千元人民幣千元人民幣千元Notes(Unaudited)(Unaudited)(Unaudited)(Unaudited)附註（未經審核）（未經審核）（未經審核）（未經審核） Revenue收入4223,171171,905438,869391,194Cost of sales銷售成本(132,856)(104,749)(251,011)(205,891) Gross profit毛利90,31567,156187,858185,303Other revenue其他收入48,3878,17810,64312,021Other net income其他收入淨額4691,6314902,318Selling and distribution expenses銷售及分銷開支(54,768)(44,059)(108,208)(121,177)Administrative expenses行政開支(19,236)(17,290)(41,600)(34,465)Other operating expenses其他經營開支(12,816)(11,169)(20,740)(17,230) Profit from operations經營溢利11,9514,44728,44326,770Finance costs財務成本6(a)(1,512)(727)(3,162)(738) Profit before taxation除稅前溢利610,4393,72025,28126,032Income tax credit/(expenses)所得稅抵免╱（開支）7(4,112)892(7,446)(3,347) Profit and total comprehensive income for the period期內溢利及全面收益 總額6,3274,61217,83522,685 中期業績（未經審核）本公司董事會（「董事會」）欣然呈列本公司及其附屬公司（統稱「本集團」）截至二零二二年六月三十日止六個月（「報告期間」）之未經審核簡明綜合中期財務報表，連同二零二一年同期之未經審核比較數字。 2SHENZHEN NEPTUNUS INTERLONG BIO-TECHNIQUE COMPANY LIMITED INTERIM REPORT 2022For the three monthsended 30 JuneFor the six monthsended 30 June截至六月三十日止三個月截至六月三十日止六個月2022202120222021二零二二年二零二一年二零二二年二零二一年RMB’000RMB’000RMB’000RMB’000人民幣千元人民幣千元人民幣千元人民幣千元Notes(Unaudited)(Unaudited)(Unaudited)(Unaudited)附註（未經審核）（未經審核）（未經審核）（未經審核） Profit/(Loss) and total comprehensive income/(expense) for the period attributable to:以下各項應佔期內溢利╱（虧損）及 全面收益╱（開支）總額：Owners of the Company本公司擁有人9,8033,99920,34419,647Non-controlling interests非控股權益(3,476)613(2,509)3,038 6,3274,61217,83522,685459 459 Earnings per share每股盈利Basic and diluted基本及攤薄9RMB0.58 centsRMB0.24 centsRMB1.21 centsRMB1.17 cents人民幣0.58分人民幣0.24分人民幣1.21分人民幣1.17分